ライフサイエンスコーパス: substance use disorder

1 ve disorders (either one co-occurring with a substance use disorder).

2 unipolar depression, anxiety disorders, and substance use disorders).

3 ) (schizophrenia) to 2.82 (2.53-3.13) (other substance use disorders).

4 rbidities (panic, PTSD, conduct disorder and substance use disorders).

5 me psychopathology (depressive, anxiety, and substance use disorders).

6 ward, which might heighten susceptibility to substance use disorder.

7 ased mortality and are more likely to have a substance use disorder.

8 riteria for a DSM-IV depressive, anxiety, or substance use disorder.

9 attention-deficit/hyperactivity disorder and substance use disorder.

10 18 years who have not been diagnosed with a substance use disorder.

11 a blurred boundary between schizophrenia and substance use disorder.

12 veryone who tries addictive drugs develops a substance use disorder.

13 ne (METH), increase relapse vulnerability to substance use disorder.

14 toms did not appear to have an impact on the substance use disorder.

15 of the 5-HTTLPR and STin2 polymorphisms with substance use disorder.

16 y, current mixed mood symptoms, and comorbid substance use disorder.

17 tes of comorbidity between schizophrenia and substance use disorder.

18 , other substance use, and family history of substance use disorder.

19 ariety of adverse health outcomes, including substance use disorders.

20 sychiatric illnesses in adulthood, including substance use disorders.

21 re are few effective strategies for treating substance use disorders.

22 by stress, such as depressive disorders and substance use disorders.

23 ities in risk-taking in the reward domain to substance use disorders.

24 development of pharmacotherapeutics to treat substance use disorders.

25 %) in women were potentially attributable to substance use disorders.

26 nds to co-occur with other disorders such as substance use disorders.

27 dual diagnosis and seek to prevent or treat substance use disorders.

28 a target for developing medications to treat substance use disorders.

29 odegeneration, dopamine neuron function, and substance use disorders.

30 hyperactivity disorder, mood disorders, and substance use disorders.

31 as a clinician-extender in the treatment of substance use disorders.

32 th proband and relative comorbid anxiety and substance use disorders.

33 re psychiatric disorders, including mood and substance use disorders.

34 e is associated with Parkinson's disease and substance use disorders.

35 e pathophysiology and potential treatment of substance use disorders.

36 es and disadvantages of the new criteria for substance use disorders.

37 rbidity is a common problem in patients with substance use disorders.

38 her protects nor increases the risk of later substance use disorders.

39 c), two brain regions strongly implicated in substance use disorders.

40 espect to increasing susceptibility to later substance use disorders.

41 practices for treating co-occurring mood and substance use disorders.

42 ological management of co-occurring mood and substance use disorders.

43 y relatively high rates of substance use and substance use disorders.

44 ng high rates of mental health disorders and substance use disorders.

45 demonstrated high rates of comorbidity among substance use disorders.

46 o 5 years to determine the onset of mood and substance use disorders.

47 derstanding the incidence and persistence of substance use disorders.

48 These reductions were not attributable to substance use disorders.

49 are system in the screening and treatment of substance use disorders.

50 psychopathology, specifically depressive and substance use disorders.

51 r hospitalization or those with psychotic or substance use disorders.

52 the Virginia Adult Study of Psychiatric and Substance Use Disorders.

53 t elevated risk to develop alcohol and other substance use disorders.

54 found to be associated with psychiatric and substance use disorders.

55 affective, anxiety, disruptive behavior, or substance use disorders.

56 eurobiological marker for the development of substance use disorders.

57 nd 20 well-matched controls without familial substance use disorders.

58 s insufficient training for physicians about substance use disorders.

59 dy, comorbid anxiety disorders, and comorbid substance use disorders.

60 and developing more effective treatments for substance use disorders.

61 .6% for mood disorders, and 0.6% to 9.0% for substance use disorders.

62 linked to anxiety and mood disorders but not substance use disorders.

63 ion, schizophrenia, cognitive disorders, and substance use disorders.

64 been implicated as potential medications for substance use disorders.

65 new directions in medication development for substance use disorders.

66 ating the vulnerability to substance use and substance use disorders.

67 resents a viable target for the treatment of substance use disorders.

68 understudied component of both gambling and substance use disorders.

69 e experiences who are at risk for developing substance use disorders.

70 populations, potentially increasing risk for substance use disorders.

71 ing disorders that is comorbid with mood and substance use disorders.

72 re the most common mental, neurological, and substance use disorders.

73 between 12-month and lifetime DUD and other substance use disorders.

74 opment in adolescents' natural resilience to substance use disorders.

75 ssociated with risk for alcoholism and other substance use disorders.

76 with early life stress and with anxiety and substance use disorders.

77 ssociated with an increased risk for several substance use disorders.

78 lopment, and neurological, mental health and substance-use disorders.

79 binge eating had a similar pattern to other substance-use disorders.

80 craving, a key factor in the maintenance of substance-use disorders.

81 isorder show greater risk-taking, similar to substance-use disorders.

82 nd impact of neurological, mental health and substance-use disorders.

83 munotherapies that use vaccination to combat substance-use disorders.

84 lect risk for a diversity of psychiatric and substance use disorders?

85 % CI, 77%-96%) and 94% (95% CI, 89%-96%) for substance use disorders, 100% and 94% (95% CI, 90%-96%)

86 hizophrenia (168.3 per 100000 person-years), substance use disorder (116.5 per 100000 person-years),

87 y disorders (39.9% compared with 21.8%), and substance use disorders (19.9% compared with 10.1%), but

88 ast one axis I or II diagnosis, most often a substance use disorder (47%).

89 rates were 12.2% (95% CI, 10.2-14.1) for any substance use disorder, 8.3% (6.6-10.0) for anxiety diso

90 depression (95% CI, 0.18-0.58), and 1.3 for substance use disorder (95% CI, 0.68-1.8).

91 onal defiant disorder, conduct disorder, and substance use disorder, ADHD remained associated with in

92 n 20 mg/d, were as follows: among those with substance use disorders, adjusted HR = 4.54 (95% confide

93 nabis use disorder was associated with other substance use disorders, affective disorders, anxiety, a

94 7), conduct disorder (97.1 [0.82]; P = .02), substance use disorders (alcohol abuse, 96.5 [0.67]; P <

95 Mental and substance use disorders alone are estimated to surpass a

96 Having a comorbid personality or substance use disorder also increased the risk of suicid

97 AHR, 2.0; 95% CI, 1.4-2.8; reference cohort, substance use disorder), an outpatient diagnosis of schi

98 , an ongoing study of youth at high risk for substance use disorder and a contrast sample of control

99 requires insurance parity for mental health/substance use disorder and general medical services.

100 er rather than specific risks for individual substance use disorders and adds to increasing evidence

101 stantial evidence of a link between parental substance use disorders and antisocial behavior and chil

102 have shown that parent-child resemblance on substance use disorders and antisocial behavior can be a

103 Parent-child resemblance for substance use disorders and antisocial behavior is prima

104 orderline, and paranoid PDs), externalizing (substance use disorders and antisocial PD), thought diso

105 he Diagnostic Interview Schedule Version IV (substance use disorders and antisocial personality disor

106 he Diagnostic Interview Schedule Version IV (substance use disorders and antisocial personality disor

107 ng adolescents, promoting the development of substance use disorders and compromised decision-making

108 orders, bipolar disorder, schizophrenia, and substance use disorders and convictions for violent crim

109 and SVM-based classifier in the diagnosis of substance use disorders and furthering an understanding

110 n may pose serious risks lies at the root of substance use disorders and is critical for mental and p

111 g adults' use of hospital-based services for substance use disorders and non-substance use psychiatri

112 We obtained data for substance use disorders and other psychiatric disorders,

113 tions in understanding its relationship with substance use disorders and underlying mechanisms of the

114 y disorders and lower levels associated with substance use disorders and violent behavior.

115 systolic blood pressure were associated with substance use disorders and violent criminality.

116 plinary treatment is provided, patients with substance use disorders and/or psychiatric diseases do n

117 stimulant that has recently been linked to a substance-use disorder and 'pharmacoterrorism' in the Mi

118 ent of addictions and related disorders, eg, substance-use disorders and binge-eating.

119 s to prevent mental health, neurological and substance-use disorders and develop effective interventi

120 a contributory factor in the maintenance of substance-use disorders and may relate to treatment resp

121 er of weeks spent with threshold depression, substance use disorder, and mixed mood symptoms and grea

122 e disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorder) and a

123 e disorder, bipolar disorder, schizophrenia, substance use disorder, and other mental disorders in re

124 njuries, major depression, bipolar disorder, substance use disorder, and other mental health conditio

125 ion between psychiatric disorders, including substance use disorder, and violent reoffending.

126 s, 100% and 94% (95% CI, 90%-96%) for severe substance use disorders, and 75% (95% CI, 52%-89%) and 9

127 ing tobacco use disorder criteria with other substance use disorders, and moving gambling disorders t

128 e a role, such as persistent pain, mood, and substance use disorders, and responses to their treatmen

129 were used to assess affective, anxiety, and substance use disorders, and self-report measures of dis

130 n, anxiety, antisocial personality disorder, substance use disorders, and suicidality (including recu

131 ch as persistent pain syndromes, depression, substance use disorders, and their comorbidity.

132 bstance use, substance use disorders, severe substance use disorders, and tobacco dependence were cal

133 cur with major depression, alcohol and other substance-use disorders, and personality disorders.

134 eating disorders, autism spectrum disorder, substance use disorders, anxiety disorders, and personal

135 disorders (AOR: 1.7; 1.5-2.0), although not substance use disorders (AOR: 1.0; 0.9-1.2).

136 isorder (AOR: 1.8; 1.4-2.2), although not of substance use disorders (AOR: 1.2; 0.9-1.5).

137 hat men with bipolar disorder and women with substance use disorders are at particularly elevated ris

138 revalence data for mental, neurological, and substance use disorders are essential for evidence-based

139 Substance use disorders are major contributors to excess

140 More data for mental, neurological, and substance use disorders are needed for India and China b

141 like behavior in rats.SIGNIFICANCE STATEMENT Substance-use disorders are often characterized as "habi

142 on deficit hyperactivity disorder (ADHD) and substance use disorders, are characterized by deficits i

143 successfully completed initial treatment for substance use disorders at a private, nonprofit treatmen

144 lity disorders, and alcohol-related or other substance use disorders at conscription and on hospital

145 umatic stress disorder (PTSD) co-occurs with substance use disorders at high rates, but the neurobiol

146 in-maintained outpatients from the Centre of Substance Use Disorders at the University Hospital of Ps

147 abuse and dependence criteria into a single substance use disorder based on consistent findings from

148 of the increase in mental, neurological, and substance use disorder burden from 1990 to 2013 (44%) th

149 , millions of individuals need treatment for substance use disorders but few receive it.

150 erial reaction time task was more evident in substance use disorders but not in obese subjects with o

151 d behavioral addiction, with similarities to substance use disorders but without the confounding effe

152 els of comorbidity between schizophrenia and substance use disorder, but little is known about the ge

153 PIT effects may play an important role in substance use disorders, but little is known about the b

154 dose is an opportunity to identify and treat substance use disorders, but treatment patterns after th

155 ne (METH), increase relapse vulnerability to substance use disorder by triggering craving.

156 , injury and neurological, mental health and substance-use disorders can result, further challenging

157 We obtained information about treatment for substance use disorders (categorised into treatment for

158 Mood and substance use disorders commonly co-occur, yet there is

159 Substance use disorders contributed only modestly to the

160 episodes and Wave 2 depression, anxiety and substance use disorders controlling for background chara

161 Interventions to address substance use disorders could substantially decrease the

162 Substance use disorders create an enormous burden of med

163 family functioning (parental mental illness, substance use disorder, criminality, family violence, ph

164 ducted analyses that were adjusted for other substance use disorder criteria in a single nucleotide p

165 in disorders (dependence and abuse), whether substance use disorder criteria should be added or remov

166 c Genomics Consortium were computed in three substance use disorder datasets: the Collaborative Genet

167 Individuals suffering from substance-use disorders develop strong associations betw

168 erdose associated with prior psychiatric and substance use disorder diagnoses ranged from 1.8 to 8.8.

169 trong associations were observed between any substance use disorder diagnosis and the polygenic risk

170 mographic characteristics, family history of substance use disorder, disturbed family environment, ch

171 Adolescents who developed substance use disorder during follow-up had significantl

172 i.e., emergency department visits related to substance use disorders) during months in which patients

173 ught to play an integral role, such as mood, substance-use disorders, eating disorders, and obesity.

174 icated (ie, persistent pain, mood disorders, substance use disorders, etc).

175 of homelessness, imprisonment, sex work, or substance use disorder (excluding cannabis and alcohol u

176 young adults with a multigenerational FH of substance use disorders exhibited smaller [(11)C]raclopr

177 This issue provides a clinical overview of substance use disorders, focusing on epidemiology, preve

178 s of the burden of mental, neurological, and substance use disorders for China and India from the Glo

179 ls (95% UI) for 15 mental, neurological, and substance use disorders for China and India in 1990 and

180 Virginia Adult Twin Study of Psychiatric and Substance Use Disorders for discordance in age at onset

181 Comorbid anxiety disorders, depression, or substance use disorders further increased the risk.

182 In influencing risk for psychiatric and substance use disorders, genes are typically conceptuali

183 ence interval, 2.73-3.25), and patients with substance use disorders had the greatest risk among wome

184 SM-IV was published in 1994, its approach to substance use disorders has come under scrutiny.

185 research agenda for global mental health and substance-use disorders has been largely driven by the e

186 ed individuals with depressive, anxiety, and substance use disorders have an earlier age at onset, gr

187 Etiologic links between obesity and substance use disorders have been hypothesized.

188 that young people at familial high risk for substance use disorders have decreased dopamine response

189 Substance use disorders have low rates of treatment rela

190 se persisted after additional adjustment for substance use disorders (hazard ratios from 1.2 to 1.8).

191 sychotropic prescriptions, and mental health/substance use disorder hospitalization bed days) remaine

192 young fathers) were at an increased risk for substance use disorders, hyperkinetic disorders, and men

193 ation patterns for mental, neurological, and substance use disorders identified in China and India em

194 isorder, and obsessive-compulsive disorder), substance use disorder (ie, drug abuse or dependence and

195 isorder in 49%, anxiety disorder in 35%, and substance use disorder in 29%.

196 e association between mortality and lifetime substance use disorder in patients with schizophrenia, b

197 rds and to better understand how to define a substance use disorder in youth.

198 rched for pleiotropic influences on comorbid substance use disorders in a novel study, and found two

199 ith first onset of common anxiety, mood, and substance use disorders in a population-based sample.

200 or the most common mental, neurological, and substance use disorders in China and India from the Glob

201 the prevalence of mental, neurological, and substance use disorders in China and India published up

202 rojected burden of mental, neurological, and substance use disorders in China and India warrants the

203 l differences) and mental, neurological, and substance use disorders in China and India, the most pop

204 M-IV mood, anxiety, disruptive behavior, and substance use disorders in respondents with a lifetime h

205 spondents, was significantly associated with substance use disorders in wave 2 (2004-2005) (any subst

206 at reducing neurological, mental health and substance-use disorders in adolescence, which is a pivot

207 neurological, psychiatric, developmental and substance-use disorders in low- and middle-income countr

208 isorders) to 11.2 (95% CI, 10.4-12.0) (other substance use disorders) in men born from 1951 to 1958 a

209 onal defiant disorder, conduct disorder, and substance use disorder increased the MRR even further.

210 Substance use disorders involving illicit and prescripti

211 merican College of Physicians maintains that substance use disorder is a treatable chronic medical co

212 t that comorbidity between schizophrenia and substance use disorder is partially attributable to shar

213 The burden of mental, neurological, and substance use disorders is estimated to increase by 10%

214 The prevalence of substance use disorders is highest during adolescence; h

215 rs correlated with mental, neurological, and substance use disorders is urgently needed to help reduc

216 tact coverage for the most common mental and substance use disorders is very low.

217 th all examined forms of psychopathology and substance use disorders, latent variable indirect effect

218 between 12-month and lifetime AUD and other substance use disorders, major depressive and bipolar I

219 complex interplay between mental health and substance-use disorders, medical conditions, and biologi

220 eatments are available for the management of substance-use disorders, mental illness, HIV and other i

221 young adults with a multigenerational FH of substance use disorders (n = 16); 2) stimulant drug-naiv

222 Substance-use disorders negatively affect the health of

223 h comorbid anxiety disorders, depression, or substance use disorders, OCD was still associated with i

224 xiety disorder does not increase the risk of substance use disorders (odds ratio=1.27; 95% CI=0.80-2.

225 nce use disorders in wave 2 (2004-2005) (any substance use disorder: odds ratio [OR], 6.2; 95% CI, 4.

226 for cause-specific mortality associated with substance use disorder of alcohol, cannabis, or hard dru

227 In bipolar disorder or depression, only substance use disorders of alcohol (bipolar disorder, HR

228 CI, 1.0-1.9; P = .04) and decreased risk of substance use disorders (OR, 0.6; 95% CI, 0.3-0.9; P = .

229 , anxiety (OR, 1.57; 95% CI, 0.40-6.09), and substance use disorders (OR, 1.64; 95% CI, 0.24-11.17) d

230 ose most in need, problems with treatment of substance use disorders, overuse of opioid medications,

231 ound in many psychiatric disorders including substance use disorders, pathological gambling, and atte

232 f clinical overlap of mania with anxiety and substance use disorders provide a basis for re-examining

233 ogical profiles of mental, neurological, and substance use disorders provides opportunities for the i

234 y is most consistent with a general risk for substance use disorder rather than specific risks for in

235 IEW: The comorbidity between psychiatric and substance use disorders remains an important phenomenon

236 inherent in the pursuit of any research; in substance use disorder research, often situated in a com

237 2010 related to the ethics of international substance use disorder research.

238 epression, generalized anxiety disorder, and substance use disorders, respondents with persistent PTS

239 in aftercare following initial treatment for substance use disorders, RP and MBRP, compared with TAU,

240 ty for identifying nontobacco substance use, substance use disorders, severe substance use disorders,

241 added or removed, and whether an appropriate substance use disorder severity indicator could be ident

242 sion: homeless populations, individuals with substance use disorders, sex workers, and imprisoned ind

243 that homeless populations, individuals with substance use disorders, sex workers, and imprisoned ind

244 ior studies have shown that individuals with substance use disorders show greater discounting (sugges

245 depression, mixed presentations, and active substance use disorder signal imminent risk for suicidal

246 Substance use disorders significantly improved the predi

247 Substance use disorders significantly increased the rate

248 d that parity did not increase mental health/substance use disorder spending and lowered out-of-pocke

249 ntributes to the development and severity of substance use disorders (substance disorders).

250 based pharmacological therapies for treating substance use disorders, such as opioid agonist treatmen

251 Substance use disorder (SUD) among anesthesiologists and

252 ge of personality disorders in the course of substance use disorder (SUD) and whether these differ by

253 Adults who remit from a substance use disorder (SUD) are often thought to be at

254 Affordable Care Act incorporated parity for substance use disorder (SUD) treatment into federal legi

255 rug use increase vulnerability to relapse in substance use disorder (SUD), and there are no pharmacot

256 rview (CIDI), which measures problem use and substance use disorder (SUD).

257 ty disorder (ADHD) is highly associated with substance use disorders (SUD).

258 the combination of severe mental illness and substance-use disorder (SUD).

259 Substance use disorders (SUDs) and human immunodeficienc

260 Substance use disorders (SUDs) are among the most common

261 Although substance use disorders (SUDs) are prevalent and associa

262 on-deficit/hyperactivity disorder (ADHD) and substance use disorders (SUDs) continues to be an area o

263 Similar to cancer, patients with substance use disorders (SUDs) present clinically with h

264 ial comorbidity between stress disorders and substance use disorders (SUDs), and acute stress augment

265 reviews current advances in the genetics of substance use disorders (SUDs).

266 everal neuropsychiatric disorders, including substance use disorders (SUDs).

267 rized by neural hyperexcitability, including substance use disorders (SUDs).

268 r depressive disorder, anxiety disorder, and substance use disorder (suicide attempts: 1.82 [1.72-1.9

269 al illness is far higher in individuals with substance use disorders than in those without, particula

270 Neurological, psychiatric, developmental and substance-use disorders that result from, or are worsene

271 an Indian) were assessed for psychiatric and substance use disorders through age 21 years (1993-2006)

272 of stigmatization of persons with mental and substance use disorders through blanket reporting laws.

273 ith those from prior neuroimaging studies in substance-use disorders, thus raising the possibility th

274 e using drugs but do not meet criteria for a substance use disorder to reduce or stop their use.

275 uthors examine patterns of comorbidity among substance use disorders to gain insight into the effect

276 tudy participants received a written list of substance use disorder treatment and mutual help resourc

277 The authors compared mental health/substance use disorder treatment use and spending before

278 increasingly promoted to engage patients in substance use disorders treatment and HIV care, but ther

279 g the opioid epidemic, insurance coverage of substance use disorders treatment, education and workfor

280 italized patients to outpatient HIV care and substance use disorders treatment.

281 m 2013 to 2025 for mental, neurological, and substance use disorders using United Nations population

282 that the association of the SLC6A4 gene with substance use disorder varies depending on substances wi

283 hites and Hispanics also had higher rates of substance use disorders vs African Americans (AOR, 1.96;

284 chizophrenia, the SMR in those with lifetime substance use disorder was 8.46 (95% CI 8.14-8.79), comp

285 A 31-year-old woman with substance-use disorder was admitted to this hospital bec

286 Substance use disorders were also an independent determi

287 isorders; bereavement, major depression, and substance use disorders were also observed, and up to 40

288 Prevalence rates of mood, anxiety, and substance use disorders were assessed using the Mini-Int

289 Psychiatric and substance use disorders were assessed with the Alcohol U

290 Ys attributable to mental, neurological, and substance use disorders were found in China and India (6

291 pressive disorder, any anxiety disorder, and substance use disorders were included in the analysis.

292 ial correlates and mental, neurological, and substance use disorders were not consistent with those r

293 In schizophrenia, all substance use disorders were significantly associated wi

294 Substance use disorders were the most common; males, how

295 d 10 years, with the exception of eating and substance use disorders, which began in adolescence (int

296 Virginia Adult Twin Study of Psychiatric and Substance Use Disorders, who reported lifetime alcohol c

297 pe, to disentangle the influence of comorbid substance-use disorders, will be a next step in identify

298 oked for papers on mental, neurological, and substance use disorders with location identifiers and so

299 rden attributed to mental, neurological, and substance use disorders within these two countries is es

300 hol-use disorder (AUD) is the most prevalent substance-use disorder worldwide.